Business
Cardiol Therapeutics Announces Year-End 2021 Update on Operations
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular diseas...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Year-End 2021 Update on OperationsExpanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditisMade strategic appointments to senior management team Listed on the NASDAQ stock exchangeEnded 2021 with cash and cash equivalents of $83.9MOakville, Ontario--(Newsfile Corp. - March 24, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (\"CVD\"), today announces its year-end 2021 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2021. Both are available under the Company's profile on SEDAR at sedar.com and on the Company's website at cardiolrx.com.David Elsley, President and Chief Executive Officer of Cardiol Therapeutics, commented: \"In 2021 Cardiol Therapeutics accomplished several important goals. We progressed novel product development, key basic research initiatives, and clinical programs focused on advancing the development of our pharmaceutically produced cannabidiol formulations for use as an anti-fibrotic and anti-inflammatory therapy in cardiovascular disease. Strategic appointments to our management team, Board of Directors, and advisory panels added invaluable industry experience and expertise. We fortified our financial position raising $98 million in gross proceeds and we listed on the Nasdaq to support our efforts to increase awareness of Cardiol within the U.S. financial community. Cardiol is now well positioned to continue pursuing its objective of developing new treatment options to improve the health and quality of life for patients living with heart disease, who are currently underserved by available therapies.\" Highlights during the 2021 Fiscal PeriodIn March, Dr. Andrew Hamer joined the Company as Chief Medical Officer (CMO). Dr. Hamer leads the research and development of Cardiol's clinical-stage products and guides the dev...